DALS — DA32 Life Science Tech Acquisition Income Statement
0.000.00%
Last trade - 00:00- $264.71m
- $264.40m
- 46
- 41
- 44
- 39
Annual income statement for DA32 Life Science Tech Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | 10-K | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Total Operating Expenses | 1.19 | 3.52 |
| Operating Profit | -1.19 | -3.52 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -1.14 | 2.28 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -1.14 | 1.2 |
| Net Income Before Extraordinary Items | ||
| Net Income | -1.14 | 1.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -1.14 | 1.2 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.045 | 0.047 |